Anadys Pharmaceuticals to Present at BIO 2004 Annual Convention.Business Editors/Health/Medical Writers BIO bi·o n. pl. bi·os Informal 1. A biography. 2. A biographical sketch or outline. 2004 Annual Convention BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--June 3, 2004 Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS) announced today that it will be presenting at the BIO 2004 Annual International Convention to be held June 6-9 at the Moscone Convention Center in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden . Michael Kamdar, Anadys' Senior Vice President of Corporate Development and Finance, will give a corporate presentation as part of the Business Forum at BIO 2004. His presentation will begin at 11:15 a.m. on Tuesday, June 8 in Level 1 of the West Building, Room B. Kleanthis G. Xanthopoulos, Ph.D., Anadys' President and Chief Executive Officer, will participate in a panel session entitled en·ti·tle tr.v. en·ti·tled, en·ti·tling, en·ti·tles 1. To give a name or title to. 2. To furnish with a right or claim to something: , "IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. Ultimate Survival Guide," following the Company's recently completed initial public offering. The panel session will begin at 11:00 a.m. on Wednesday, June 9 in the West Building, Room 2004. Anadys Pharmaceuticals, Inc. (www.anadyspharma.com) is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule, anti-infective medicines for the treatment of hepatitis C virus
Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic virus and bacterial infections. Anadys is advancing its anti-infective portfolio through the development of its two clinical programs, the isatoribine family of compounds and ANA380. In addition, Anadys' anti-infective therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion